Drug Approval | April 28, 2026
AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease
The submission is backed by positive results from the Phase 3 AFFIRM study
The submission is backed by positive results from the Phase 3 AFFIRM study
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The approval was driven by data from the Phase III TULIP-SC trial
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
nSEPIA aims to bring structure to an area long dominated by subjectivity
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
Subscribe To Our Newsletter & Stay Updated
